Methylprednisolone Alternatives Compared
Methylprednisolone | Dupixent | Rinvoq |
|
---|
Methylprednisolone | Dupixent (dupilumab) | Rinvoq (upadacitinib) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Methylprednisolone effectively controls inflammation and an overactive immune system but may not be suitable for everybody. Long-term use is limited by potentially severe side effects such as... View more |
Prescription only
Dupixent injection is usually given every 1 to 4 weeks to treat asthma, eczema, chronic rhinosinusitis, COPD, eosinophilic esophagitis, or prurigo nodularis. Injection site reactions and eye problems... View more |
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid... View more |
Related suggestions Atopic Dermatitis
|
|||||||||||||||||||||||
More about Methylprednisolone | More about Dupixent (dupilumab) | More about Rinvoq (upadacitinib) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Methylprednisolone has an average rating of 7.1 out of 10 from a total of 474 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 24% reported a negative effect. |
Dupixent has an average rating of 7.1 out of 10 from a total of 464 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 22% reported a negative effect. |
Rinvoq has an average rating of 6.8 out of 10 from a total of 192 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: methylprednisolone side effects in more detail. |
See also: Dupixent side effects in more detail. |
See also: Rinvoq side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all methylprednisolone prices |
View all Dupixent prices |
View all Rinvoq prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Depo-Medrol, Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack, Solu-Medrol |
N/A |
Other upadacitinib brands include: Rinvoq LQ | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
3.5 hours |
N/A |
14 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
Excluding First Trimester
Category D
Positive evidence of risk
First Trimester See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 592 drugs are known to interact with methylprednisolone:
|
A total of 76 drugs are known to interact with Dupixent:
|
A total of 580 drugs are known to interact with Rinvoq:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
October 24, 1957 |
March 28, 2017 |
August 16, 2019 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.